Moreover, in the KRAS*-bearing mice that survived for 60 days after the initiation of IRE + anti-PD1 treatment, all rejected tumor cell re-challenge, along with an anti-tumor memory T cell response. The gene discussed is PDCD1; the disease is neoplasm.